Small molecule tyrosine kinase inhibitors (TKIs), such as imatinib, bosutinib, dasatinib, nilotinib, radotinib, and ponatinib, have been developed to treat CML by blocking the kinase domain of the BCR-ABL oncoprotein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.